Drafting Detailed Drug Patent Claims: The Art and Science of Pharmaceutical IP Protection
1. The Economic Architecture of the Patent Bargain 1a. What the Patent System Actually Incentivizes The pharmaceutical patent system rests […]
The Chiral Switch: A Complete Technical and Strategic Guide to Single-Enantiomer Drug Development, IP Valuation, and Evergreening Litigation
A definitive reference covering stereochemical science, the 1992 FDA policy and its commercial aftershocks, chiral separation technology roadmaps, Forest Labs
FDA Tentative Approvals: The Definitive Guide to Forecasting Generic Drug Entry
How to read the FDA’s most underused signal, map the Hatch-Waxman timeline with precision, and turn patent intelligence into a
FDA Tentative Approvals: The Definitive Guide to Forecasting Generic Drug Entry Read Post »
The Patent Trial and Appeal Board: The Definitive Analyst’s Guide to IPR Strategy, Pharmaceutical IP Valuation, Discretionary Denial Mechanics, and the Post-Arthrex Power Shift
1. Why the PTAB Is the Single Most Important Variable in Pharmaceutical Patent Valuation Analysts who model pharmaceutical patent portfolios
How to Win Drug Patent Disputes: The Complete IP Strategy Guide for Pharma Decision-Makers
The revenue locked inside a single patent grant can exceed the GDP of a small country. AbbVie’s Humira franchise generated
Drug Patent Opposition: The Complete Playbook for Pharma IP Teams, Generic Challengers, and Portfolio Investors
1. What Patent Opposition Actually Is, and What It Costs A patent opposition is a formal administrative procedure at a
Drug Delivery Complexity: The IP Moat That Keeps Generics Out for Decades
The pharmaceutical patent cliff narrative has dominated investor and analyst conversations for two decades, but it increasingly misses the point
Drug Delivery Complexity: The IP Moat That Keeps Generics Out for Decades Read Post »
Nonprofit Pharma’s Real Playbook: IP Strategy, Cost-Plus Pricing, and the Patent Data Advantage
What Nonprofit Pharma Actually Is (And Isn’t) Understanding the Structural Distinction ‘Nonprofit pharma’ covers at least three distinct entity types,
The Biosimilar Patent Dance and PTAB Playbook: How to Win the Biologic IP War
1. The Economics Driving the Biosimilar IP War The global biosimilar market is not a niche regulatory experiment. It is
The Biosimilar Patent Dance and PTAB Playbook: How to Win the Biologic IP War Read Post »
